The goal of this pilot is to determine the therapeutic efficacy and safety of two formulations of vitamin D analog 25,25,25,27,27,27-Hexafluoro-1 Alpha, 25-dihydroxyvitamin D3 for treatment of plaque psoriasis in adults. This will be accomplished by evaluating the topical application of two petrolatum-based formulations containing F6-1, 25(OH)2D3. The safety and efficacy of these two formulations will be compared with the safety and efficacy of placebo vehicle or Dovonex, a commercially available prescription product which contains a vitamin D analog. A total of up to 45 adults patients with plaque type psoriasis who have lesions over at least 5% of their bodies will be studied. Study subjects will be male and female between the ages of 18-80. The study will be for a total of two months of treatment. One of the test materials will be applied by the patient at the dose of approximately 0.05G to a 25 CM2 lesion. A comparable 25 CM2 psoriasis lesion will receive 0.05 of second test material. The third lesion will receive either 0.05G of petrolatum or Dovonex.
Showing the most recent 10 out of 476 publications